On June 6, 2017, it was announced that Marina Biotech, Inc. (OTCQB: MRNA) – a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, acquired Prestalia®, a treatment of hypertension, from Symplmed Pharmaceuticals LLC. 

Prestalia may be used in patients whose blood pressure is not adequately controlled on monotherapy, and it may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Prestalia is protected by two patents listed in the U.S. FDA's publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The two Prestalia U.S. patents offer the potential for product exclusivity until 2029.

It is anticipated that Prestalia will be marketed using Symplmed's patented telehealth technology platform, DyrctAxess™, which enables direct delivery of medications to a patient's home and helps to address the problem of poor compliance resulting from unfilled prescriptions.

The Pryor Cashman Team

Representing Marina Biotech in this deal were Pryor Cashman Partner Lawrence Remmel and Counsel Michael T. Campoli – both of whom are members of the firm's nationally-recognized Corporate Group.